Using longitudinal Medicare claims data, this study quantified the association of the Medicare Part D coverage gap with medication adherence among beneficiaries with chronic obstructive pulmonary disease.
Evaluation of cancer patients’ quality of life at admission enabled improvement of their satisfaction with received care at discharge.
A randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional face-to-face consultations.
Enrollees in Medicaid plans employing prior authorization policies for opioid medications may have lower rates of opioid medication abuse and overdose.
Nurse practitioner prescribers exhibited a high rate of contact with pharmaceutical industry promotional activities.
Authors from My Gene Counsel discuss gaps in CMS reimbursement policy for genetic testing and counseling, in light of advances in guidelines from groups that include the National Comprehensive Cancer Network.
We surveyed biopharmaceutical manufacturers and payers to understand the prevalence and characteristics of value-based payment arrangements, as well as their implementation obstacles and success factors.
An original emergency department patient survey, insurance claims data, and administrative records are used to examine the characteristics of nonurgent users.
Member cost negatively affects initial medication adherence and manufacturer coupons can decrease member share by up to 98%.
A quality measure reduced antibiotic use for patients with acute bronchitis but led to use of an alternative diagnosis, offsetting most of the observed improvement.
Several evidence-based health literacy resources may be beneficial in health plan settings to improve organizational health literacy, personal health literacy, and health equity.
Enhanced care coordination in New York City that leveraged surveillance data with a health plan’s Medicaid managed care roster improved its HIV viral load suppression rate.
Patients with an insomnia diagnosis have higher healthcare utilization and costs than a matched control group, both before and after the diagnosis.